News

The patent illustrates the company’s Morphodoma technology, a whole genome evolution platform that can enhance cells producing monoclonal antibodies to yield daughter cells producing antibodies with enhanced pharmacologic

The suspensions were announced after the Committee for Medicinal Products for Human Use (CHMP) initiated ‘Article 107’ procedure on November 16, 2007. This occurs when an EU member

Endo Pharmaceuticals and Penwest Pharmaceuticals manufacture and market Opana ER for the treatment of moderate to severe pain. Impax’s submission includes a paragraph IV certification stating the company

R84 selectively blocks vascular endothelial growth factor (VEGF) binding only to VEGFR2, the receptor primarily responsible for tumor angiogenesis, unlike Avastin and other drugs in development that block

The hits identified from Nerviano Medical Sciences (NMS) HT screening campaign will be optimized in terms of their potency, selectivity, in-vitro ADME profile with the subsequent progression into

Under the terms of the agreement, Specialized Health Products will provide finished goods to Braun Medical for marketing under Braun’s private label and branded as Surecan SafeStep. The

This safety and efficacy study follows the successful completion of a Phase I safety, tolerability and pharmacokinetics trial in healthy volunteers and the previously executed preclinical toxicology program.

This agreement amends a prior agreement Boston Scientific reached in July 2007 to cover additional unanticipated claims. Boston Scientific acquired Guidant in 2006. Under the terms of the

With this approval, patients will be able to calibrate the system without using a connection cable. DexCom expects to launch this feature to new patients near the end